推荐产品
生物源
mouse
品質等級
抗體表格
purified immunoglobulin
無性繁殖
9B3.2, monoclonal
物種活性
human
製造商／商標名
Chemicon®
技術
immunofluorescence: suitable
同型
IgG2a
運輸包裝
wet ice
特異性
Influenza A H1N1 antigen. No reactivity shown to Influenza B strains.
SPECIES REACTIVITY:
Reacts strongly with the following H1N1 strain: Beijing. A/ Texas /36/91, A/Berkeley/1/98, A/HongKong/503/97,A/Nanchang /16A/98,A/PR8/34 and New Caledoniastrain.
SPECIES REACTIVITY:
Reacts strongly with the following H1N1 strain: Beijing. A/ Texas /36/91, A/Berkeley/1/98, A/HongKong/503/97,A/Nanchang /16A/98,A/PR8/34 and New Caledoniastrain.
免疫原
Epitope: H1N1
Influenza blend
應用
IF
Optimal dilutions must be determined by end user
Optimal dilutions must be determined by end user
Research Category
Infectious Diseases
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
Infectious Diseases - Viral
This Anti-Influenza A Antibody, H1N1, clone 9B3.2 is validated for use in IF for the detection of Influenza A.
外觀
Format: Purified
Purified immunoglobulin. Liquid in 0.02 M Phosphate Buffer + 0.25 M Sodium Chloride + 0.1% Sodium Azide, pH = 7.6
儲存和穩定性
Store at 2° to 8°C for up to 12 months from date of receipt.
其他說明
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
法律資訊
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
免責聲明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
儲存類別代碼
10 - Combustible liquids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Sialylneolacto-N-tetraose c (LSTc)-bearing liposomal decoys capture influenza A virus.
Hendricks, GL; Weirich, KL; Viswanathan, K; Li, J; Shriver, ZH; Ashour, J; Ploegh et al.
The Journal of Biological Chemistry null
Kristina L Prachanronarong et al.
Journal of virology, 93(2) (2018-11-02)
Influenza A virus (IAV), a major cause of human morbidity and mortality, continuously evolves in response to selective pressures. Stem-directed, broadly neutralizing antibodies (sBnAbs) targeting the influenza virus hemagglutinin (HA) are a promising therapeutic strategy, but neutralization escape mutants can
Li Jiang et al.
Journal of virology, 96(6), e0198221-e0198221 (2022-01-20)
Many oseltamivir resistance mutations exhibit fitness defects in the absence of drug pressure that hinders their propagation in hosts. Secondary permissive mutations can rescue fitness defects and facilitate the segregation of resistance mutations in viral populations. Previous studies have identified
Evolution of the influenza A virus genome during development of oseltamivir resistance in vitro.
Renzette, N; Caffrey, DR; Zeldovich, KB; Liu, P; Gallagher, GR; Aiello, D; Porter et al.
Journal of virology null
Shaopeng Wang et al.
Proceedings of the National Academy of Sciences of the United States of America, 107(37), 16028-16032 (2010-08-28)
We report on label-free imaging, detection, and mass/size measurement of single viral particles in solution by high-resolution surface plasmon resonance microscopy. Diffraction of propagating plasmon waves along a metal surface by the viral particles creates images of the individual particles
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门